Talphera Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Talphera has been growing earnings at an average annual rate of 40.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 40.7% per year.

Anahtar bilgiler

40.2%

Kazanç büyüme oranı

52.9%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı-40.7%
Özkaynak getirisi-107.7%
Net Marj-3,443.2%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well

Aug 18

AcelRx Pharmaceuticals: Finally, Plan B

Jun 06

AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers

Mar 16

AcelRx Pharmaceuticals: The Fog Is Getting Thicker

Jan 14

AcelRx: Battered And Bruised But Ready For Recovery In 2022

Jan 05

AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?

Oct 02

AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm

Jul 27

FDA agrees with AcelRx to update promotional materials for Dsuvia

Jun 17

Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now

Jun 11
Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now

AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles

May 31

Gelir ve Gider Dağılımı

Talphera nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGM:TLPH Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-14100
31 Mar 241-14110
31 Dec 231-10120
30 Sep 230-11140
30 Jun 230-14160
31 Mar 23058170
31 Dec 22054170
30 Sep 22-26920
30 Jun 22-16570
31 Mar 222-31270
31 Dec 210-17150
30 Sep 214-36330
30 Jun 213-37300
31 Mar 216-33310
31 Dec 205-40360
30 Sep 205-46410
30 Jun 204-50460
31 Mar 202-55480
31 Dec 192-53450
30 Sep 192-51400
30 Jun 192-51340
31 Mar 192-49270
31 Dec 182-47210
30 Sep 182-44170
30 Jun 183-45160
31 Mar 185-48160
31 Dec 178-52170
30 Sep 1714-51170
30 Jun 1716-50170
31 Mar 1717-48160
31 Dec 1617-43160
30 Sep 1613-44160
30 Jun 1625-28140
31 Mar 1622-25130
31 Dec 1519-24140
30 Sep 1518-28150
30 Jun 157-32170
31 Mar 155-34190
31 Dec 145-33180
30 Sep 1433-2170
30 Jun 1428-13150
31 Mar 1429-20120
31 Dec 1330-23100

Kaliteli Kazançlar: TLPH is currently unprofitable.

Büyüyen Kar Marjı: TLPH is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: TLPH is unprofitable, but has reduced losses over the past 5 years at a rate of 40.2% per year.

Büyüme Hızlandırma: Unable to compare TLPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: TLPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Özkaynak Getirisi

Yüksek ROE: TLPH has a negative Return on Equity (-107.65%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin